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54Mycophenolic acid (MPA) is an important immunosuppressant broadly used in renal
transplantation. However, the large inter-patient variability in mycophenolic acid
(MPA) pharmacokinetics (PK) limits its use. We hypothesize that extrahepatic
metabolism of MPAmay have significant impact onMPA PK variability. Two intestinal
UDP-glucuronosyltransferases 1A8 and 1A10 plays critical role in MPA metabolism.
Both in silico and previous genome-wide analyses suggested that vitamin D (VD)
may regulate intestinal UGT1A expression. We validated the VD response elements
(VDREs) across the UGT1A locus with chromatin immunoprecipitation (ChIP) and
luciferase reporter assays. The impact of 1-alpha,25-dihydroxyvitamin D3 (D3) on
UGT1A8 and UGT1A10 transcription and on MPA glucuronidation was tested in hu-
man intestinal cell lines LS180, Caco-2 and HCT-116. The correlation between tran-
scription levels of VD receptor (VDR) and the two UGT genes were examined in
human normal colorectal tissue samples (n 5 73). PK alterations of MPA following
the parent drug, mycophenolate mofetil (MMF), and D3 treatment was assessed
among renal transplant recipients (n 5 10). Our ChIP assay validate three VDREs
which were further demonstrated as transcriptional enhancers with the luciferase as-
says. D3 treatment significantly increased transcription of both UGT genes as well as
MPA glucuronidation in cells. The VDRmRNA level was highly correlated with that of
both UGT1A8 and UGT1A10 in human colorectal tissue. D3 treatment in patients led toto this work.
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Volume 178 Wang et al 55about 40% reduction in both AUC0-12 and Cmax while over 70% elevation of total
clearance of MPA. Our study suggested a significant regulatory role of VD on MPA
metabolism and PK via modulating extrahepatic UGT activity. (Translational
Research 2016;178:54–62)Abbreviations: AcMPAG ¼ acyl mycophenolic acid glucuronide; ChIP ¼ chromatin immuno-
precipitation; Cmax ¼ maximum concentration; DR ¼ direct repeat; MMF ¼ mycophenolate
mofetil; MPA¼mycophenolic acid;MPAG¼mycophenolic acidglucuronide; PK¼pharmaco-
kinetics; PD¼ pharmacodynamics; TDM¼ therapeutic drugmonitoring; UGT¼ UDP-glucurono-
syltransferase; VDR ¼ Vitamin D3 receptor; VDRE ¼ Vitamin D response elementENTARY
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Mycophenolate mofetil (MMF) is increasingly used
as an important immunosuppressant to prevent acute
rejection after kidney transplantation. Recent clinical
studies have consistently suggested that including
MMF is superior to other immunosuppressant combina-
tions in maintaining renal function, in the development
of adverse effects, as well as in graft and patient
survival.1-4 However, inter-patient variability in its
pharmacokinetics (PK) limits its full potential in clin-
ical applications.5,6 MMF is a prodrug which is
hydrolyzed into its active form mycophenolic acid
(MPA) after oral intake.5 It has been shown that the
extent of MPA exposure is highly correlated with acute
allograft rejection.7 About 20% of patients discontinue
the medication due to the adverse events such as gastro-intestinal disorders and bone marrow suppression which
were suggested to be associated with the free MPA frac-
tion.7,8 In spite of numerous studies to date, the
mechanism underlying this inter-patient PK variability
of MMF/MPA has not been completely elucidated.6 In
order to individualize the MMF dosage, current MMF
administration protocols increasingly apply therapeutic
drug monitoring (TDM).7,9 Therefore, identifying
factors affecting MMF/MPA PK is of particular
importance to achieve more effective and safer use of
this drug.
Inter-patient PK variability are largely attributed to
the variable activities of drug metabolism pathways.
Previous studies have demonstrated that MPA is mainly
metabolized via glucuronidation by UDP-
glucuronosyltransferases (UGTs) in both the liver and
intestine, which produces a major phenolic glucuronide,
mycophenolic acid glucuronide (MPAG), and a minor
acyl glucuronide (AcMPAG).10-14 UGTs catalyze the
formation of hydrophilic glucuronides, which is one
of the important detoxification processes in human
metabolism.15 The human UGTs consists of 4 families,
UGT1, UGT2A and 2B, UGT3, and UGT8, of which,
UGT1, UGT2A and UGT2B are primarily involved in
drug metabolism and are encoded by genes located on
chromosome 2 and 4, respectively.15-17 Variability in
UGT activity has been significantly associated with
inter-individual differences in metabolism of a broad
array of endogenous and exogenous compounds
including many therapeutic agents.18 Previous studies
have revealed that glucuronidation of MPA mainly in-
volves UGT1A8 and UGT1A9, with UGT1A10 and
UGT2B7 playing a minor role.10-14 While UGT1A9
and UGT2B7 are important hepatic UGTs whose roles
in MPA metabolism have been widely investigated,
UGT1A8 and UGT1A10 are the only two UGT1A
enzymes expressed in human intestinal tissue
including the small intestine, colon and rectum,15,19
and their roles in MPA PK variability has drawn only
limited attention. It has been suggested that intestinal
UGTs are also critical to the metabolism of many
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of these two enzymes may also significantly
contribute to the inter-patient difference in both the
pharmacokinetics and pharmacodynamics of MMF/
MPA.
On the other hand, as one of the most important tran-
scription factors in human intestinal tissue, the vitamin
D receptor (VDR) plays a crucial role in regulating a
large number of genes.22,23 A recent genome-wide
study using a human intestinal cell line LS180 revealed
that UGT1A locus harbors multiple vitamin D response
elements (VDREs), and UGT1A gene expression is
significantly induced by 1-alpha,25-dihydroxyvitamin
D3 [1a,25(OH)2D3] treatment.
24 Given that only 1 cell
line was tested in this study, additional VDREs may
also exist e.g. in a cell-specific manner, we further per-
formed an in silico screening for putative VDREs (the
most common DR3-type)25 in the UGT1A8 and
UGT1A10 region as well as the entire UGT1A locus.
We have identified a number of putative VDREs in
this region. On the other hand, our previous study has
suggested that VDR is not a significant regulator for he-
patic UGTs, further underscores the importance of po-
tential VDR-UGT regulation in intestinal tissues. We
therefore hypothesize that VD/VDR is an important
regulator for intestinal UGTs 1A8 and 1A10, which
may further influence the MPA metabolism. In order
to corroborate this hypothesis, we performed studies
in human colorectal cancer cell lines and tissue samples
aiming to: 1) validate the binding of VDR to the putative
VDREs; 2) examine the effects of 1a,25(OH)2D3 treat-
ment in regulating UGT1A8 and UGT1A10 mRNA
expression and enzyme activity in MPA glucuronida-
tion; and 3) examine the effects of 1a,25(OH)2D3 on
MMF/MPA PK profiles in human kidney transplanta-
tion patients.
METHODS
Human tissue samples and kidney transplantation
patients. Human colorectal (n5 73) mucosa tissue sam-
ples were collected at the time of surgery from patho-
logically documented colorectal cancer patients at the
Shanghai First People’s Hospital (Shanghai, China)
with informed consent and conformation with institu-
tional guidelines. All collected normal tissue were
.5 cm away from the primary tumor site. The patients
are all Han Chinese in origin with a median age of
68 years, and 50% of whom were female.
Kidney transplantation recipients (n 5 10) were re-
cruited to test the impact of vitamin D on the MPA
PK profiles. Patient information was summarized in
Table SII. All participants are inpatients of the Trans-
plantation Center at the Shanghai First People’s Hospi-tal. Informed consent was obtained from all participants
and was in conformation with institutional guidelines.
The collection of human tissue samples as well as the
human subject study was approved by Institutional Re-
viewBoard (IRB) of theShanghai First People’sHospital.
In silico screening for putative VDREs. The most typical
DR (direct repeat) 3-type VDRE was screened by a
bioinformatic analysis (detailed in supplement
methods) of the genomic sequence spanning the entire
UGT1A gene locus as well as 6100kb flanking
sequences (a total of 352,020 bp).
Chromatin immunoprecipitation (ChIP) assay. The
ChIP assay (detailed in supplement methods) was
performed in LS180, Caco-2 and HCT-116 cells under
treatment with 1028 M 1a,25(OH)2D3 or vehicle
(ethanol) at 1, 8 and 24 hr time points, respectively.
Cloning and luciferase assay. The DNA fragments
containing the putative VDREs were cloned into the
pGL3-Promoter (pGL3-P) vector (Promega, WI,
USA), and transiently transfected into the LS180 cells,
respectively, using Lipofectamine 2000 Transfection
Reagent (Life Technologies, CA, USA) according to
the manufacturer’s instructions. After 24 hrs of
transfection, luciferase activity was compared between
the transfection of pGL3-Promoter (pGL3-P) and
pGL3-Promoter-VDRE vectors with or without
1a,25(OH)2D3 treatment (10
28 M) by using the Dual-
Luciferase Reporter Assay System (Promega).
Real-time PCR. Transcription levels of UGT1A8,
UGT1A10 and/or VDR in the cell lines before and after
1a,25(OH)2D3 treatment (10
28 M for 24 hrs), as well as
in human normal colorectal tissue samples (n 5 73)
were quantified with real-time PCR.
Effects of 1a,25(OH)2D3 treatment on MPA
glucurondiation in cell lines. LS180, Caco-2 and HCT-
116 cells were treated with 1a,25(OH)2D3 (10
28 M)
or vehicle for 24 or 48 hrs, followed by co-incubation
with MPA (2 mM) and UDPGA (0.5 mM) for
additional 4 hrs. MPA glucuronidation rates were
measured using HPLC/MS/MS. Briefly, the peak areas
of MPA and MPAG were calculated and the ratio of
MPAG/MPA were normalized to the mean values of
the ratios of triplicates. These normalized ratios were
then reported as the endpoint data. Assays were
performed in triplicates and repeated twice. (See
details in supplement methods).
Effect of 1a,25(OH)2D3 treatment on MPA PK profiles
in vivo. We recruited kidney transplantation recipients
(n 5 10) who all underwent kidney transplantation
14–15 days prior to the PK study. Baseline Creatinine,
Creatinine Clearance (CrCL) and albumin levels for
all patients were collected (Table SII). Cyclosporine A
(CsA) and prednisone were administrated for all
Fig 1. Chromatin Immunoprecipitation (ChIP) assays for validating
the VDR binding to the UGT1A locus. A). ChIP assays for VDRE16
identified from the 50-flanking sequence of UGT1A8 exon 1 region
among all 3 cell lines. B). ChIP assays for CS1 and CS2 identified
in previous ChIP-seq study24 in LS180. Note that two amplicons
were examined in the CS1 region. Data were shown for the time points
at 1, 8 and 24 hr of treatment with 1a,25(OH)2D3 or vehicle (ethanol)
only. A significantly stronger band in the anti-VDR group as compared
to the IgG group (negative control) indicates a positive VDR binding
to the region.
Fig 2. Regulatory function of the identified VDREs as transcriptional
enhancers by luciferase assay. Data are shown as mean 6 SD.
**P, 0.01. P values were calculated based on the comparison in rela-
tive luciferase activity (ratios between firefly and renilla signals) of
each vector between the vitamin D and vehicle treated (24 hrs) groups.
Vh 5 vehicle, VD 5 1a,25(OH)2D3.
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250 ng/ML and 1200–1500 ng/ML, respectively for
every patient and prednisone for 16 mg PO, q.d.
MMF (Hoffman-La Roche) (1 g/dose, every 12 hrs)
was administrated to all patients for one week. Plasma
MPA concentrations were monitored on day 8 for
12 hrs. MMF (same dose as aforementioned) and Ro-
caltrol (Calcitriol, Hoffman-La Roche) (0.25 mg/dose,
once daily) were co-administrated to the patients for
additional one week. On day 16, plasma MPA concen-
trations were measured again at the same time points as
in day 8 for 12 hrs. The experimental design was sum-
marized in Fig. S3. Patients were screened by physical
examination and detailed laboratory tests were con-ducted if necessary. Patients who had co-morbid dis-
ease or liver function that deviated from the normal
range were excluded from the study. All enrolled pa-
tients did not smoke or drink alcohol, and were in-
structed to maintain a regular diet during the trial
without any use of supplements, Chinese medicine or
other treatments.
Quantification of plasma MPA was conducted by
mixing patient plasma sample (20 mL) and acetonitrile
(800 ml) containing internal standard (osalmid, 96 ng/
ml), followed by centrifugation 12000 rpm for 10 min.
The supernatant was used to detect MPA using LC-
MS/MS with similar settings as mentioned above.
Pharmacokinetic analysis. Pharmacokinetic parame-
ters were estimated using a noncompartmental anal-
ysis. The maximum serum MPA concentrations
(Cmax) and time to reach Cmax (Tmax) were deter-
mined by visual inspection of the serum MPA
concentration-time curves. The terminal elimination
rate constant (k) was calculated by least-squares
linear regression of the log-linear portion of the
serum concentration-time curves. The area under the
serum concentration-time curve from 0 to 12 hours
(AUC0-12) was calculated using the linear trapezoidal
rule. Since MMF is rapidly and completely
hydrolyzed to MPA, the oral clearance (CL/F) of
MPA was estimated by the ratio of the MMF dose
(corrected for differences in the molecular weight)
and the AUC of the dosing interval.
Data analyses and statistics. Comparison between
treatments in cell lines was conducted using an unpaired
t-test. The correlation between VDR and UGT gene
Fig 3. Induction of UGT1A8 and UGT1A10 by the 1a,25(OH)2D3 treatment in Caco-2 (A) and LS180 (B) cells.
Data were shown as mean6 SD for each treatment group. The ratio of expression level between eachUGT relative
to that of the 18S gene was normalized to that of the control group. *P, 0.05; **P, 0.01. P values were calcu-
lated based on the comparison between the 1a,25(OH)2D3 treatment group and control group. Transcription levels
of both UGT1A8 and UGT1A10 were not detectable in HCT-116 before and after 1a,25(OH)2D3 treatment and
therefore were not shown.
Fig 4. Induction of UGT activities for glucuronidation of MPA by
1a,25(OH)2D3 in Caco-2, HCT-116 and LS180 cells. The ratio be-
tween MPAG and MPA levels was normalized to that of the control
group. Data were shown as mean 6 SD for each treatment group.
*P , 0.05; **P , 0.01. P values were calculated based on the com-
parison between the 1a,25(OH)2D3 treatment group and control group
for each cell line.
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paired t-test was used to compare the difference in PK
parameters before and after vitamin D treatment in
transplantation patients. The type I error rate was set
to 0.05 for all comparisons. Data were analyzed and
plotted using Graphpad InStat 3.0 and Prism 6.0,
respectively (CA, USA).RESULTS
Identification and confirmation of the VDREs in the
UGT1A region. Our bioinformatic analysis of 200 kb
region of the entireUGT1A locus reveals a total of 83 pu-
tative DR3-type VDREs in the region, with 13 of which
distributed within the UGT1A8-UGT1A10 6 10kb
region (see supplemental Table SI for more details).
However, the two ChIP-seq identified VDREs were not
predicted in our list, suggesting that they might be
motifs that are different from DR3-type.
To validate these VDR binding sites, we used three
human colorectal cancer cell lines: LS180, Caco-2
and HCT-116. We first conducted ChIP assays for the
two ChIP-seq identified VDREs (CS1 and CS2) as
well as 4 putative VDREs (No. 16, 17, 21 and 22)
closest to the UGT1A8 or UGT1A10 exon 1 region
(Table SI). Positive binding of VDR to the locus 16
(VDRE16) (approximately 5.5kb upstream from
UGT1A8 exon 1, Chr 2: 234,520,791–234,520,805)
was observed in all 3 cell lines especially at the time
point of 24 hr (Fig 1A). Both ChIP-seq identified
VDR binding regions showed strong VDR binding after
24 hrs of vitamin D treatment in LS180 (Fig 1B) but not
in Caco-2 or HCT-116 (Fig. S2). No significant binding
of VDR to the remaining 3 tested loci (17, 21 and 22)
has been observed (data not shown).
Cloning and luciferase assay. To further validate the
D3 regulation on UGT1A8 and UGT1A10 gene expres-
sion, we respectively cloned the three DNA fragments
(CS1, CS2 and VDRE16) into the upstream region of
Fig. 5. Pearson correlation between the gene expression of VDR and
UGT1A8 (A) and UGT1A10 (B) in human normal colorectal tissue
samples. The expression of VDR and UGT genes was relative to that
of the 18S gene. The ratios were further normalized to the lowest value
of the 73 samples and log transformed (1log10).
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Transient transfection of all three constructs into the
LS180 demonstrated that these VDR binding sites
significantly enhanced the reporter gene promoter
activity under 1a,25(OH)2D3 treatment as compared
to the pGL3-Promoter vector or the control group
with vehicle only. The luciferase activity was
increased about 40–60% in these cells after
1a,25(OH)2D3 treatment (P, 0.05 for all tests) (Fig 2).
Induction of UGT1A8 and UGT1A10 expression by
1a,25(OH)2D3 treatment. We then tested whether the
transcription of both UGT genes was inducible by
1a,25(OH)2D3. After treatment of all 3 cells with
1a,25(OH)2D3 for 24 hrs, significantly increased
expression of both UGT1A8 and UGT1A10 wasobserved in LS180 and Caco-2 but not in the HCT-
116 cell line (Fig 3). The induction of both UGT1A8
and UGT1A10 was dose-dependent in Caco-2 and
LS180, respectively, with significantly increased
expression of both genes observed in both cell lines
under the higher concentration (1028 M) (P , 0.05
for all tests). Real-time PCR analysis demonstrated
that both UGT genes were not detectable in HCT-
116 cell lines with or without any treatment (data not
shown).
Regulation of MPA glucuronidation activity in vitro by
1a,25(OH)2D3. We further examined whether MPA
metabolism is altered after 1a,25(OH)2D3 induction
for UGT1A8 and UGT1A10 expression. All 3 cells
were treated with 1a,25(OH)2D3 for 24 hrs or 48 hrs
and theMPA glucuronidation productMPA glucuronide
(MPAG) was measured. We found that MPA glucuroni-
dation activity in both Caco-2 and LS180 was
significantly increased 1.6- and 2.5-fold after 48 hrs of
induction, respectively (P , 0.002), but not in the
HCT-116 cells (P 5 0.22) (Fig 4), which is consistent
with the induction results for the transcription of two
UGTs by 1a,25(OH)2D3 among these 3 cells.
Gene expression of VDR, UGT1A8 and UGT1A10 genes in
humancolorectal tissue. In order to examinewhether the
VDR regulation for both UGT genes also exists in vivo,
we quantified the mRNA levels of all three genes in a set
of normal colorectal tissue samples (n5 73). We found
that all three genes were highly expressed in human
colorectal tissue. There was a highly significant positive
correlation in the expression level between VDR and the
UGT1A8 (r5 0.49, P, 0.0001) orUGT1A10 (r5 0.77,
P , 0.0001) gene (Fig 5).
Impact of 1a,25(OH)2D3 on MMF/MPA
pharmacokinetics. Based on the aforementioned mech-
anistic study in vitro or ex vivo, we hypothesize that
1a,25(OH)2D3 intake may significantly change the
MMF/MPA pharmacokinetics. To test this hypothesis,
we compared the PK profile of MPA before and after
1a,25(OH)2D3 intake in human kidney transplantation
recipients (n 5 10). We found that one-week of
1a,25(OH)2D3 treatment significantly reduced the
MPA AUC0-12 and maximum concentration (Cmax)
by about 40% in these patients (P 5 0.0008 and
P 5 0.003, respectively), while the oral clearance
(CL/F) of MPA was significantly increased over 70%
(P 5 0.008) (Fig 6). No statistically significant
relationships were observed between age, gender,
BMI or weight with these parameters (P . 0.05, data
not shown). Effect of other clinical factors including
Cr, CrCL and Albumin levels on PK parameter
changes were also tested and no statistically
significant impact were observed (P . 0.05, data not
shown).
Fig. 6. Impact of 1a,25(OH)2D3 on MPA pharmacokinetics: A) MPA concentration changes in 12 hours; B)
Paired comparison of MPA area-under-the-curve (AUC0-12). Data for each time point was shown as
mean 6 SEM; C) Paired comparison of MPA Cmax; and D) Paired comparison of MPA clearance.
VD 5 1a,25(OH)2D3.
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Our study for the first time demonstrates that vitamin
D significantly alters the metabolism of MPA by modu-
lating the expression of two intestinal UGTs in vitro.
This effect may further lead to an altered MPA pharma-
cokinetics when MPA and vitamin D are co-
administrated. This modulation may in part explain
the inter- and intra-individual differences in MPA PK
observed clinically. More importantly, our findings
have critical clinical implications. Previous studies
have indicated that the MPA PK parameters are signifi-
cantly associated with various clinical outcomes in renal
transplant recipients as well as adverse events.4,6,7 This
calcitriol-MPA interaction, especially during calcitriol
co-administration or dietary supplementation may
potentially reduce the efficacy of MMF and increase
the risk of organ rejection. This is particularly an issue
as osteoporosis e.g. bone loss and fracture, is a commonand serious morbidity in kidney transplantation, and
calcitriol is increasingly used to reduce the accelerated
bone loss in renal transplant recipients.26,27
Understanding the inter-individual variability in the
gene expression of drug metabolism enzymes in
different tissues or organs is tremendously important
for individualizing medication. Compared to hepatic
UGTs, there are very limited studies on the genetic basis
for the regulation of UGT1A8 and UGT1A10, which are
predominantly expressed in human intestinal tissue.15,19
Our study suggests that intestinal regulation of UGT
genes is also important in the pharmacokinetics of
therapeutic agents. Although other UGTs e.g.
UGT1A9 and UGT2B7 were also shown to be
involved in MPA glucuronidation,10-14 our previous
study demonstrated that VDR is not a significant
regulator for hepatic UGTs.28 This suggests that this
vitamin D-UGT modulation may be tissue-specific. It
Translational Research
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hepatic metabolism in order to completely understand
the inter-patient variability in MPA PK and/or efficacy.
In addition, given the numerous therapeutic agents that
are substrates of UGT1A8 and/or UGT1A10,18,21,29-34
we suggest that caution should be exercised when
vitamin D is co-administered.
Given the large number of in silico-predictive puta-
tive VDREs at the UGT1A locus, we did not validate
all of them in our study. Rather, we focused our valida-
tion on the putative VDREs closest to the UGT1A8 and
UGT1A10 regions. Our subsequent in vitro and ex vivo
assays strongly suggested that intestinal UGT1A8 and
UGT1A10 are VD-regulated genes. This finding is
consistent with the recent genome-wide ChIP-seq study
by Meyer MB et al,24 where VDR binding sites were
identified in the UGT1A region and UGT1A transcrip-
tion was significantly induced by vitamin D treatment
in the LS180 cell. However, the VDRE16 identified in
our study was not observed in this ChIP-seq assay in
LS180, and our confirmatory assay also did not observe
the two loci identified in their study in Caco-2 and HCT-
116 cells. While this may be due to the different cell
lines used which further reflects a potential cell-
specific usage of the VDREs, it also suggests that addi-
tional types of VDREs are located in the region since no
DR3-type of VDRE was predicted in the two loci
identified by the ChIP-seq. Further analyses are now
ongoing in the lab to elucidate the detailed VDR binding
mechanism to these VDREs. Nevertheless, our results
combined with the findings inMeyer’s study provide ev-
idence that multiple VDREs may be distributed in the
entire locus. As ChIP-seq has been the unequivocal
strategy in identifying transcription factor-binding
DNA elements, a comprehensive ChIP-seq analysis in
multiple cell lines derived from intestinal tissue under
different treatment options may eventually unravel the
detailed mechanism underlying the VDR regulation of
the two UGTs.
We did not observe induction of either UGT in HCT-
116 cells, although the ChIP assay demonstrated a
strong VDR binding to the identified VDRE16 in this
cell (Fig 2). An explanation is that additional mecha-
nisms may be involved in the inactivation of the two
UGT genes in this cancer cell line. There is no expres-
sion of the two UGT genes in the non-treated HCT-
116 cells in our real-time PCR assay, which was in
contrast to the relatively higher basal expression in the
Caco-2 or LS180 cells (data not shown). Interestingly,
it has been reported that DNA methylation represses
UGT1A1 expression in colon cancer cells, in particular
HCT-116.35,36 It is thus reasonable that a similar
mechanism may be involved in the inactivation of
UGT1A8 and UGT1A10 in this cell.MPA is a widely used and important immunosuppres-
sant medication that requires specific therapeutic levels
for optimal clinical efficacy. The potential clinical im-
plications of our findings clearly support more research
to further elucidate the regulation of these two UGT en-
zymes by vitamin D and the VDR. This research is all
the more imperative, given the ubiquitous and seem-
ingly innocuous clinical practice of providing vitamin
D supplementation to patients.ACKNOWLEDGMENTS
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METHODS
Bioinformatic analysis. The entire UGT1A locus and
6100kb flanking region (a total of 352,020 bp) were
screened for putative VDREs. Although there are
different types of VDREs, we only focused on the
most typical DR3 type consensus sequence, i.e. the
direct repeat (DR) of the hexameric core sequence
RGDKYR (R 5 G or A, D 5 A, G or T, K 5 G or T,
Y5 C or T).1 The online ‘‘DNA Pattern Find’’ program
(http://www.ualberta.ca/stothard/javascript/dna_patte
rn.html) was used for the motif screening.
Cell culture and treatment with 1a,25(OH)2D3. Caco-2,
HCT-116 and LS180 cell lines were obtained from
American Type Culture Collection (Manassas, VA,
USA) and maintained in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum, 50 mg/ml
penicillin, 0.25 mg/ml streptomycin, and 2 mM L-gluta-
mine at 37C with 5% CO2.Cells were treated with
1a,25(OH)2D3 (Sigma, MO, USA) at 10
29 M and
1028 M for 1, 8, 24 or 48 hrs for different tests.
Effects of 1a,25(OH)2D3 treatment on MPA glucuronida-
tion incell lines. MPA glucuronidation was quantified us-
ing HPLC/MS. Briefly, the sample preparation followed
that of Klepacki, et al.2 In short, protein precipitation
was performed using a solution of 30% 0.2 M ZnSO4
in water and 70% methanol. Separation was performed
on an Agilent Rapid Res 1200 HPLC system using an
Agilent Zorbax XDB-C8 (2.1 3 50 mm, 3.5 mm) col-
umn. Mobile phase A was water with 0.1% formic
acid and 2 mM NH4Ac. Mobile phase B was 5% water
and 95% methanol, with 0.1% formic acid and 2 mM
NH4Ac. Gradient elution was used, increasing mobile
phase B from 30% to 100% in 10 min. The column
was re-equilibrated at 30% B for 5 minutes prior to sub-
sequent injection. A flow rate of 0.3 mL/min was used.
Retention time for MPAwas 8.8 minutes and for MPAG
was 6.7 minutes.
Analytes were quantified by MS/MS utilizing an
Agilent 6460 triple quadrupole mass spectrometer
with positive electrospray ionization (ESI). A frag-
mentor energy of 125 V and a dwell time of 150 ms
was used. Source parameters were as follows: nitro-
gen gas temp 5 325C and flow rate 5 9 L/min,
nebulizer pressure 5 35 psi, sheath gas temperature
5 275C, sheath gas flow rate 5 7 L/min, and capil-
lary potential 5 3.0 kV. Quantitation was based on
Multiple Reaction Monitoring (MRM). Maximum
sensitivity was obtained by monitoring the corre-
sponding sodium and ammonium adducts, as the pro-
tonated adduct response was negligible.3 Respective
adduct responses were summed for calculations.
For MPA, [MPA 1 Na]1 m/z 343.0 to 229.1 and[MPA 1 NH4]1 m/z 338.0 to 207.0. For MPAG,
[MPAG 1 Na]1 m/z 519.0 to 229.1 and
[MPAG 1 NH4]1 m/z 514.0 to 207.0. All transitions
used a collision energy of 15 eV and a dwell time of
150 ms. All data were collected and analyzed with
Agilent Mass Hunter B.03 software. To calculate
the MPA-MPAG turnover rate, MPA and MPAG
peak areas were quantified. The detection limits
(peak area) for MPA and MPAG are 600 and 45,
while the MPA and MPAG peak areas in the samples
ranged 1 million to 4 million and 2000–50000,
respectively. Therefore the peak areas were all well
above the detection limits.
Chromatin Immunoprecipitation (ChIP) assay. Caco-2,
HCT-116 and LS180 cells were treated with 1028 M
1a,25(OH)2D3 or vehicle (ethanol) for 1, 8 and
24 hours, respectively. The cells were cross-linked
by adding 270 mL formaldehyde to 10 mL medium
for 10 min, and the reaction was stopped by
0.125 M glycine (final concentration). Cell lysates
were sonicated to generate 200–1,000 bp DNA frag-
ments. Antibodies against VDR (Millipore-Chemicon,
MO, USA) were used to immunoprecipitate the DNA-
protein complexes. Normal IgG was used as a negative
control. After an overnight incubation with the anti-
body, the immune complexes were collected using
80 mL of protein A Agarose slurry (Upstate Biotech-
nology, CA, USA). The beads were washed twice
with the following buffers (Upstate Biotechnology,
CA, USA): low salt washing buffer, high salt wash
buffering, LiCl washing buffer, and TE buffer. The
DNA was eluted with 1% SDS and 0.1 M NaHCO3
elution buffer, and then subjected to reverse cross-
linking, proteinase digestion, and purification using a
commercial kit (Qiagen, Valencia, CA). Among the
83 candidate VDREs, 4 (No. 16, 17, 21, and 22 see
Table SI) were tested for VDR binding. We hypothe-
sized that these 4 loci are the closest to UGT1A8
and UGT1A10 exon 1s, which may possess strongest
regulation for these two UGT genes. The primers










two VDR binding sites (CS1 and CS2) identified in
the recently published ChIP-seq study in LS180 cell4
were also tested in our samples. These two loci were
Translational Research
62.e2 Wang et al December 2016located at chr2:234,668,582–234,669,759 and
chr2:234,672,790–234,673,397 (hg19). The primers







pectively. PCR amplification was cycled 35 times at
95C for 10s, 56C for 20s and 72C for 30s after pre-
heating at 95C for 10 min. The PCR products were
separated and visualized by electrophoresis with 2%
Agarose gel. ChIP assays were repeated three times
and the representative data are shown. A typical electro-
phoretic separation of the ChIP-PCR products in agrose
gel was shown in Fig. S1.
Cloning and luciferase assay. The DNA fragment of
185 bp, 330 bp and 178 bp containing VDRE16,CS1-
1 and CS2 were generated with PCR and cloned into
the pGL-3-Promoter (pGL3-P) vector containing the
firefly luciferase gene (Promega, WI, USA). For the
CS1 site, we only cloned the CS1-1 fragment as this
site was demonstrated to have the strongest VDR bind-
ing in the ChIP assay (Fig 1). Cloned sequences were
verified by sequencing. For luciferase assay, the pRL-
TK plasmids containing a renilla luciferase gene (Prom-
ega) was co-transfected with pGL3-P or pGL3-P-VDRE
vectors into LS180 cells, using Lipofectamine 2000 Re-
agent (Invitrogen, CA, USA) according to manufac-
turer’s instruction. Cells were treated with vehicle
(ethanol) or 1028 M 1a,25(OH)2D3 for 24 hs after the
transfection. Cells were then harvested and the firefly
and renilla luciferase activities were then measured by
using the Dual-Light Luciferase Assay Kit (Promega)
according to the manufacturer’s instructions. The firefly
luciferase activity was normalized to that of the renilla
to obtain the relative activity. For plotting the data, all
measurements were also normalized to the relative ac-
tivity value of the pGL3-Ptransfection treated with
vehicle only. Experiments were repeated twice and the
representative data are shown.
DNA and RNA extraction and reverse transcription. The
total RNA of the cells as well as both the RNA and DNA
of the human colorectal tissue samples were extracted
by using the RNA/DNAMini Kit (Qiagen, Hilden, Ger-
many). The integrity of the cell and tissue RNA was
checked by separated in 1% Agarose gel (Fig. S1),
and concentration was measured by ultraviolet spectros-
copy. Complementary DNA (cDNA) was made by
reverse transcription of total RNA (1 mg) by using the
High-Capacity cDNA Archive Kit (Applied Bio-
systems, CA, USA).Real-time PCR. Gene expression levels of UGT1A8,
UGT1A10 and/or VDR were quantified with real-time
PCR by using the SYBR Green Super Mix (Bio-Rad,
CA, USA) in the Eppendorf Realplex real-time PCR
system (Eppendorf, Germany) according to the protocol
previously established in the lab.5,6 Briefly, amplicons
in UGT1A8 and UGT1A10 (161 bp and 187 bp,
respectively), amplified with primers spanning exon 1
and 2, and VDR (107 bp), sequence spanning exons 6–
7, were generated by real-time PCR. The ribosomal
18S rRNA gene and beta-actin gene (ACTB) were used
as internal controls.5,6 Primer sequences used for the
three genes were UGT1A8F: 50-CACATCAATTTGG
TTGTTGCGACCA-30; UGT1A8R: 50-CCACAATTC
CATGTTCTCCAG-30; UGT1A10 F: 50-GTCACGGC
ATATGATCTCTACGGT-30, UGT1A10 R: 50-CCAC
AATTCCATGTTCTCCAG-30; and VDRF: 50-TCCTC
CTGCTCAGATCACTG-30, VDRR: 50-AGGGTCACA
GAAGGGTCATC-30. Reactions were performed with
standard curves for each gene and repeated twice.
Real-time PCR was cycled 45 times at 95C for 30s,
63C (UGT1A8 and UGT1A10) or 55C (VDR,18S
and ACTB) for 1 min and 72C for 30s after preheating
at 95C for 10 min. The relative expression levels of
UGT1A8, UGT1A10 and VDR were normalized by
that of 18Sor ACTB, respectively. For each gene, the ra-
tio of its expression relative to 18Sor ACTB was then
normalized to that of the sample with the lowest gene
expression level.
Real-time PCR for UGT1A8 and UGT1A10 in the in-
duction assay was performed using the same conditions
mentioned above. The ratio of UGT gene expression
relative to 18Swas normalized to that of the cells treated
with vehicle only.
Pharmacokinetic analysis in kidney transplantation re-
cipients. Patient information was summarized in
Table SII. The experimental design for the clinical
investigation was shown in Fig S3.
Statistical analyses. Gene expression (relative ratio
between each target gene and 18S rRNA or ACTB
gene) was log transformed (1log10) prior to the cor-
relation analysis. Comparison of the induction of
UGT gene expression as well as luciferase activity
between the cells treated with different concentra-
tion of 1a,25(OH)2D3 and vehicle only were per-
formed with non-paired t-test. Inter-individual
variability in the expression of UGT1A8 and
UGT1A10 gene was defined by using the median
and distribution range. Correlations between the
VDR gene and each UGT gene were performed using
Pearson correlation. P 5 0.05 was set as the cut-off
for statistical significance. All statistical analysis
was performed and plotted using GraphPad Prism
Fig S1. A typical semi-quantitative ChIP assay separated in agrose
gel. Showing here is the ChIP-PCR reaction in LS180 cells for
VDRE16 element under 1h vit D treatment.
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Volume 178 Wang et al 62.e3version 6.0 for Windows (GraphPad Software, San
Diego, CA, USA).
RESULTS
ChIP assay. No significant binding of VDR to the two
loci (CS1 and CS2) identified by the previous ChIP-seq
study4 was observed in Caco-2 or HCT-116. Results of
the ChIP assays for these loci are shown in Fig. S2.
Candidate VDREs identified from the UGT1A8-UGT1A10
region. Table SI listed all identified candidate VDERs
in the UGT1A locus. These are putative DR3-type
VDREs in the UGT1A6100kb region. The core motifs
are highlighted in bold. The position of start and end nu-
cleotides of the core motifs on chromosome 2 were
based on the human genome assembly hg19 (2009).
The four putative VDREs (16, 17, 21 and 22) tested
for VDR binding using ChIP assay were highlightedin red. Note that the exon 1 of UGT1A8 and
UGT1A10 is between 16 and 17, and 21 and 22,
respectively.
Fig S2. ChIP assay for CS1 and CS2 in Caco-2 and HCT-116 cells.
MMF 1.0g/dose, twice/day
1     2     3     4     5     6     7     8     9    10   11  12   13   14   15   16 
7:30am MMF 1st dose                           7:30pm MMF 2nd dose
Time:     8        9      10     11     12      1       2        3       4       5        6       7       8
Vit D 0.25μg/day, once/day
7:30am                                                        7:30pm
Vit D+MMF 1st dose                           MMF 2nd dose 
Time:    8       9      10     11     12      1        2        3       4       5        6       7       8
Time points for blood sample collection
Time scale
Day:
Fig S3. Experimental design for the pharmacokinetic study of MPA.
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Table SI. Putative VDREs identified in the UGT1A locus
Putative VDRE Locus ID Start End Strand
AGTGTGTCAGGGTTG 1 234427278 234427292 Reverse
AGATTGGTTAGGTTA 2 234439010 234439024 Reverse
AGATTATATGGAGCA 3 234444375 234444389 Forward
GGTTTATCAAGTTTA 4 234447063 234447077 Reverse
GGGGTGGAGAGGTCG 5 234469459 234469473 Forward
AGGGCAGTTAGTGTA 6 234474507 234474521 Forward
AGTGTACAGGGTTTG 7 234474516 234474530 Forward
AGGGTGTCAAGTTTG 8 234489577 234489591 Forward
AGGTCAGTGGGTGCG 9 234492359 234492373 Reverse
GGTTCAGAAAGTTTG 10 234503975 234503989 Forward
GGTTCAGAAAGTTTG 11 234505369 234505383 Forward
AGTTTGCAGAGATCA 12 234505807 234505821 Forward
GGTTTGAAGAGTTTA 13 234515068 234515082 Reverse
GGTTCATTCAGGGTA 14 234516819 234516833 Forward
GGTTTGTTGAGATCA 15 234519930 234519944 Reverse
AGGTTGATGGGTGTA 16 234520791 234520805 Reverse
AGAGTAGCCAGTTTA 17 234528550 234528564 Forward
AGGGTGTAGGGTGCA 18 234529015 234529029 Reverse
AGGGTGTCAAGATCA 19 234532422 234532436 Forward
GGTGCACTTGGTGTA 20 234534743 234534757 Forward
AGTTTATGTGGTTTA 21 234536946 234536960 Forward
AGAGTAGCCAGTTTA 22 234547178 234547192 Forward
GGTGCAGGAAGATTA 23 234549637 234549651 Reverse
GGAGTAGAAAGTTTA 24 234550733 234550747 Reverse
AGGGTAACTGGTGTG 25 234555186 234555200 Reverse
GGTTTGCCCAGATTA 26 234563963 234563977 Forward
AGAGTAGCCAGTTTA 27 234582594 234582608 Forward
AGGTTGTGGGGTGCA 28 234583091 234583105 Reverse
AGTTTGACAAGTGTG 29 234584706 234584720 Forward
AGTGTGTCAAGATCA 30 234584715 234584729 Forward
GGTGCACTTGGTGTA 31 234587120 234587134 Forward
AGATCATAAAGAGTG 32 234593405 234593419 Forward
AGGTTGGTGGGTTTA 33 234602510 234602524 Forward
AGTTTATTGAGAGTG 34 234605455 234605469 Forward
AGGGTGGGGAGATTA 35 234614156 234614170 Forward
AGGGCAGCTGGATTG 36 234614896 234614910 Forward
AGGGCACGAGGGGTA 37 234619441 234619455 Reverse
AGATTGGATGGATCA 38 234622847 234622861 Reverse
AGATCACTCAGGTCA 39 234625405 234625419 Forward
GGGTTAAATGGATTA 40 234632436 234632450 Reverse
GGGGTAGGGGGAGCG 41 234642603 234642617 Forward
AGAGCATCTGGAGTG 42 234645457 234645471 Reverse
GGATTATGGGGATTA 43 234646664 234646678 Reverse
AGGGTGGTGGGAGTG 44 234652957 234652971 Forward
AGATTAATTGGATTG 45 234655396 234655410 Forward
GGAGCAGAAAGAGCA 46 234656533 234656547 Reverse
GGATTATGGGGATTA 47 234658300 234658314 Reverse
AGGGTGGTGGGAGTG 48 234664308 234664322 Forward
GGTTCATAAAGGGTA 49 234665499 234665513 Forward
AGGGTATTAGGTGTA 50 234665508 234665522 Forward
GGAGCACACAGAGTA 51 234670019 234670033 Reverse
AGGTCAATAGGTGCA 52 234674286 234674300 Forward
AGAGTGGGAGGATCA 53 234676370 234676384 Reverse
GGGGCAAAAAGAGCA 54 234676474 234676488 Reverse
GGGTCAGGGGGTTCG 55 234682594 234682608 Forward
GGGTCGTTGGGGTCA 56 234687923 234687937 Forward
GGTGCAGTAAGAGTG 57 234695888 234695902 Forward
GGTGCACTCAGGGTG 58 234700576 234700590 Forward
AGGGCAGCAGGGTTG 59 234701359 234701373 Forward
(Continued )
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Table SII. Demographic (age, gender) and clinical (BMI, blood levels of Creatinine (Cr), Albumin and
clearance of Creatinine (CrCL)) information for the kidney transplantation recipients (n 5 10)
Patient ID Gender Age BMI Cr (mmol/L) CrCL (mL/min) Albumin (g/L)
1 F 57 22.9 96 76 41.1
2 M 40 19.4 88 68 39.6
3 M 30 21.6 105 86 40.9
4 M 53 22.8 109 84 42
5 M 40 20.5 98 75 44.8
6 M 38 22.1 93 72 40.4
7 M 50 23.5 104 85 40.2
8 M 43 20.2 102 82 43.4
9 F 32 25.4 102 78 43.9
10 M 42 20.1 102 70 39.3
Table SI. (Continued )
Putative VDRE Locus ID Start End Strand
AGTTTGTTAGGGTTG 60 234703413 234703427 Forward
AGGGTGGGTGGGGTG 61 234704971 234704985 Forward
GGGGTAGGCAGGGTG 62 234704998 234705012 Forward
GGTGTGGGGAGGGTA 63 234705145 234705159 Reverse
GGATTGTTGAGTGCA 64 234705929 234705943 Reverse
AGTGTATTAAGTGTA 65 234706167 234706181 Forward
AGATTGCACAGGTTG 66 234709678 234709692 Reverse
GGTTTGATGAGTGTG 67 234710522 234710536 Forward
AGAGTGAGAGGGGCA 68 234711578 234711592 Reverse
AGGGCAGAGGGAGTG 69 234718204 234718218 Reverse
AGATTAACAGGTTCA 70 234722047 234722061 Forward
AGATTAGGCAGTGCA 71 234723774 234723788 Forward
AGGGTGGTGAGTTTG 72 234730061 234730075 Reverse
AGGGCGGTGGGTGCA 73 234731212 234731226 Forward
GGTGTGGGCGGGGTG 74 234732328 234732342 Forward
GGGTCGATAGGTGCA 75 234736286 234736300 Forward
GGGGTGGTGAGTGCA 76 234739372 234739386 Reverse
AGTGCAACCAGGGCA 77 234741413 234741427 Forward
GGAGTGTGGGGAGCA 78 234746490 234746504 Reverse
GGGTCAGTGGGAGTG 79 234748628 234748642 Reverse
AGGGCGGCAGGAGCA 80 234759576 234759590 Forward
AGTGTGAATGGAGTA 81 234762437 234762451 Reverse
AGTGTACATAGGTTA 82 234774476 234774490 Reverse
GGGGTGGCTGGTTCA 83 234775336 234775350 Forward
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